Introducing ‘GLP-3s’: The Next Frontier in Weight-Loss Medication

A new generation of weight-loss drugs, informally dubbed ‘GLP-3s,’ are showing remarkable promise in clinical trials, potentially offering a more effective alternative to current treatments. These innovative medications target multiple hormone receptors, aiming to enhance weight loss and improve related health conditions.

• ‘GLP-3s’ are investigational drugs that act as triple agonists, targeting GLP-1, GIP, and glucagon receptors.
• The most advanced example, retatrutide by Eli Lilly, has demonstrated significant weight loss in trials, exceeding that of some existing medications.
• Beyond weight loss, these drugs have shown potential benefits for conditions like knee osteoarthritis.
• While promising, potential side effects and long-term safety are still under close observation.

Building upon the success of GLP-1 agonists, which mimic a hormone that regulates appetite and blood sugar, ‘GLP-3s’ represent a significant advancement. These new drugs are triple agonists, meaning they activate three key hormone receptors: GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This multi-target approach is believed to be more effective in promoting weight loss.

Eli Lilly’s investigational drug, retatrutide, is a prime example of a GLP-3. Unlike GLP-1 agonists that target one hormone, or drugs like tirzepatide that target two (GLP-1 and GIP), retatrutide targets all three. The glucagon component is thought to help the body burn stored fat for energy, contributing to greater weight reduction.

Clinical trials for retatrutide have yielded impressive results. In one study involving participants with obesity and knee osteoarthritis, those taking a 12 mg dose of retatrutide lost an average of 28.7 percent of their body weight over 68 weeks. This significant weight loss also correlated with substantial improvements in knee pain and physical function.

Another trial reported a 24.2% weight reduction after 48 weeks with a 12 mg once-weekly injection, with participants continuing to lose weight beyond the trial period.

The enhanced efficacy of GLP-3s could offer a powerful tool for individuals struggling with significant weight loss needs and associated health complications, such as type 2 diabetes, cardiovascular risks, and orthopedic issues. However, as with current weight-loss medications, potential side effects are a consideration. Common side effects reported include gastrointestinal issues like nausea, vomiting, and diarrhea. Increases in heart rate have also been noted, depending on the dosage. The long-term safety profile, particularly concerning the glucagon-agonist component, is still being closely monitored by healthcare professionals.

While retatrutide is still undergoing clinical trials, with further Phase 3 readouts expected, its potential approval could mark a new era in weight management. Experts suggest that these drugs may offer outcomes comparable to bariatric surgery, though careful medical supervision will be crucial due to the novel mechanisms and potential risks involved. The development of GLP-3s signifies a major step forward in the pharmaceutical approach to obesity and metabolic health.

• ‘GLP-3s’ explained as clinical trials show they are more effective than current weight loss jabs, UNILAD.
• ‘GLP-3’ retatrutide drug delivers major weight loss breakthrough in trials, Fox News.